Reaction
Low Density Lipoprotein Decreased reporting signals
As of the last recalculation, Low Density Lipoprotein Decreased appears in 1,400 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is INCLISIRAN (PRR 193.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Inclisiran | 97 | 193.1 | 195.5 |
| Evolocumab | 726 | 137.2 | 137.8 |
| Quinapril Hydrochloride | 41 | 79.6 | 80.0 |
| Alirocumab | 115 | 74.2 | 74.5 |
| Glyburide | 45 | 28.5 | 28.6 |
| Linagliptin | 29 | 24.1 | 24.2 |
| Ezetimibe | 110 | 23.6 | 23.6 |
| Octreotide Acetate | 41 | 20.5 | 20.5 |
| Loperamide Hydrochloride And Dimethicone | 41 | 19.6 | 19.6 |
| Rosuvastatin | 226 | 19.4 | 19.4 |
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 9 | 15.8 | 15.8 |
| Rosuvastatin Calcium | 27 | 14.5 | 14.5 |
| Loperamide Hydrochloride | 41 | 14.0 | 14.0 |
| Icosapent Ethyl | 7 | 12.3 | 12.3 |
| Oxymorphone Hydrochloride | 7 | 9.0 | 9.0 |
| Memantine | 7 | 7.6 | 7.6 |
| Memantine Hydrochloride | 7 | 7.6 | 7.6 |